Hangzhou – October 28, 2026 -- Lynk Pharmaceuticals reported that its oral JAK1 inhibitor zemprocitinib sustained a 91.8% ACR20 response rate at Week 76 in rheumatoid arthritis patients who had failed or could not tolerate biologic therapy, with no new safety signals in the pivotal Phase III trial.